• Facebook
  • Instagram
  • Youtube
  • Linkedin
  • Twitter
  • Registry
  • ERBP
  • Working Groups
    • CKD-MBD
    • DESCARTES
    • DIABESITY
    • ERN
    • EUDIAL
    • EURECA-m
    • IWG
    • WGIKD
  • Committees
    • SAB
    • YNP
    • ECC
    • GNC
    • NPPC
    • Ethics Committee
    • Registry
    • ERBP
ERA-EDTA
  • ABOUT ERA-EDTA
      • WHO WE ARE
      • History
      • ERA-EDTA Facts and Dates
      • Pioneers of the European Nephrology
        • Interviews with the Masters of Nephrology
      • Obituaries
      • Mission
      • ORGANIZATION & GOVERNANCE
      • Council
        • Council Members
        • Past Council Members
        • Committees, Roles and Terms
        • Candidatures Boards and Calls
      • ORGANIZATION & GOVERNANCE
      • Group & Staff
        • ERA-EDTA
          • ERA-EDTA Operative Headquarters
        • ERA-Eurocongress Ltd
      • Constitution
      • Code of Conduct
      • Disclosure of Interest (DoI)
      • Annual Reports
      • Accounts
      • ERA-EDTA Membership
      • Benefits
      • Fees
      • Renewal
      • Members: Senior – Junior
      • Honorary Members
      • AWARDS
      • Awards 2020
      • Awards 2019
      • Awards 2018
      • ERA-EDTA Distinguished Fellow (FERA)
  • CONGRESS & MEETINGS
    • Berlin 2021
    • Paris 2022
    • Past Congresses
    • Scientific and Educational Interaction Day (SEID)
    • CTDay
    • CEPD
    • ERA-EDTA CME Courses
  • VIRTUAL MEETING
  • SCIENCE
    • Long Term Fellowships
    • Research Programme
    • Registry Fellowships
    • Registry
    • ERACODA
  • EDUCATION
    • NEP-Nephrology Education Portal
    • Virtual Meeting
    • e-seminars
    • GlomCon Webinars
    • Short Term Clinical Fellowships
    • ERA-EDTA CME Courses
    • Patient Information
      • Initiatives for patients
      • Patient Associations
    • ERA-EDTA Endorsement/Non-Financial Support
    • European Specialty Examination in Nephrology (ESENeph)
    • COVID-19 News and Information
  • NETWORKING
  • GUIDELINES
  • JOURNALS & PRESS
      • NDT
      • CKJ
      • Cardio-renal research
      • EDTA Proceedings
      • Newsletter & Press Releases
        • Nephrology News Flash
        • NEP Newsletter
        • Press Releases
      • News
      • EDTA Proceedings
      • Press and Social Media Policies
  • PUBLIC AFFAIRS
    • Collaboration with Societies
    • National Societies
      • National Societies of Nephrology List
    • ASN ERA-EDTA ISN Collaboration
    • EKHA
    • Biomedical Alliance in Europe
    • ERA-EDTA Endorsement/Non-Financial Support
    • Link Exchange
  • Search
  • Menu
  • My ERA-EDTA
  • Contact us
  • MEMBERSHIP
  • MEMBERSHIP
  • My Era-Edta
  • Contact us
  • ABOUT ERA-EDTA
    • Who we are
      • History
      • ERA-EDTA Facts and Dates
      • Mission
    • Organization & Governance
      • Council
        • Council Members
        • Past Council Members
        • Committees, Roles and Terms
    • Group & Staff
      • ERA-EDTA
      • ERA-EDTA Operative Headquarters
      • ERA-Eurocongress Ltd
      • Constitution
      • Code of Conduct
      • Annual Reports
      • Accounts
    • ERA-EDTA Membership
      • Benefits
      • Membership Fees
      • Renewal
      • Members: Senior – Junior
    • AWARDS
      • Awards 2020
      • Awards 2019
      • Awards 2018
      • ERA-EDTA Distinguished Fellow (FERA)
  • CONGRESS & MEETINGS
    • Berlin 2021
    • Paris 2022
    • Scientific and Educational Interaction Day (SEID)
    • CTDay
    • CEPD
    • ERA-EDTA CME Courses
  • VIRTUAL MEETING
  • SCIENCE
    • Long Term Fellowships
    • Research Programme
    • Registry Fellowships
    • Registry
    • ERACODA
  • EDUCATION
    • NEP-Nephrology Education Portal
    • Virtual Meeting
    • e-seminars
    • GlomCon Webinars
    • Short Term Clinical Fellowships
    • ERA-EDTA CME Courses
    • Initiatives for patients
    • Patient Associations
    • ERA-EDTA Endorsement/Non-Financial Support
    • European Specialty Examination in Nephrology (ESENeph)
    • COVID-19 News and Information
  • NETWORKING
  • GUIDELINES
  • JOURNALS & PRESS
    • NDT
    • CKJ
    • Cardio Renal Research
    • Newsletter & Press Releases
      • Nephrology News Flash
      • NEP-Nephrology Education Portal Newsletters
      • Press Releases
    • News
    • EDTA PROCEEDINGS
    • Press and Social Media Policies
  • PUBLIC AFFAIRS
    • Collaboration with Societies
    • National Societies
    • ASN ERA-EDTA ISN Collaboration
    • EKHA
    • ERA-EDTA Endorsement/Non-Financial Support
    • Link Exchange
  • Registry
  • ERBP
  • Working Groups
    • CKD-MBD
    • DESCARTES
    • DIABESITY
    • ERN
    • EUDIAL
    • EURECA-m
    • IWG
    • WGIKD
  • Committees
    • SAB
    • YNP
    • ECC
    • GNC
    • NPPC
    • Ethics Committee
    • Registry
    • ERBP

Tag Archive for: chronic kidney disease

Posts

Which phosphate transporters should be targeted to reduce hyperphosphatemia?

News, News-Home

NaPi-IIb, a type II sodium-dependent phosphate transporter, is considered a dominant transporter in rodents for phosphate absorption in the small intestine. However, the regulation of its expression in chronic kidney disease (CKD) is still ambiguous. A recent study measured protein expression level of NaPi-Iib in CKD-rats by mass spectrometry to evaluate the extent of phosphate transport via this molecule. The results showed that  the contribution of NaPi-IIb to intestinal phosphate absorption dramatically decreases in CKD, suggesting that in order to improve handling of hyperphosphatemia in CKD it is mandatory to inhibit other phosphate transporters as well.

Read the full article here: https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfaa156/5900877

 

14 October 2020/by ERA-EDTA
https://www.era-edta.org/en/wp-content/uploads/2020/10/m_gfaa156f3.png 241 520 ERA-EDTA ERA-EDTA2020-10-14 10:02:322020-10-14 10:02:32Which phosphate transporters should be targeted to reduce hyperphosphatemia?

Great news for patients with Chronic Kidney Disease: SGLT2 inhibitors slow disease progression

Press Releases
Read more
31 August 2020/by ERA-EDTA
0 0 ERA-EDTA ERA-EDTA2020-08-31 12:56:532020-09-10 14:08:02Great news for patients with Chronic Kidney Disease: SGLT2 inhibitors slow disease progression

Dysregulated turnover of collagen type III is an important determinant of chronic kidney disease progression

News, News-Home

Collagen type III (COL3) is one of the most abundant extracellular matrix components in the human body; decreased urinary levels of a degradation fragment of COL3 (C3M) were associated with the severity of CKD in patients with immunoglobulin A nephropathy and kidney allograft failure. Genovese et al. assessed the relationship between fragments reflecting active formation (PRO-C3) and degradation (C3M) of COL3 and CKD disease progression and mortality in 500 patients from the Renal Impairment in Secondary Care study. In a paper recently published in Clinical Kidney Journal they concluded that products of COL3 formation and degradation were independently associated with CKD progression and mortality, thus representing an opportunity to link pathological processes with targeted treatments against fibrosis.

Read full text at https://academic.oup.com/ckj/advance-article/doi/10.1093/ckj/sfz174/5704451

27 February 2020/by ERA-EDTA
https://www.era-edta.org/en/wp-content/uploads/2020/02/m_sfz174f1.png 459 520 ERA-EDTA ERA-EDTA2020-02-27 09:55:352020-02-27 10:02:29Dysregulated turnover of collagen type III is an important determinant of chronic kidney disease progression

Serum bicarbonate as a cardiovascular risk factor

News, News-Home

Cardiovascular disease (CVD) remains the leading cause of death in chronic kidney disease (CKD) patients. Metabolic acidosis is a risk factor for CVD and increases overall mortality risk in CKD patients, but also in the general population. An editorial by D. E. Wesson in Nephrology Dialysis Transplantation (NDT) explores available evidence on the mechanisms through which acidosis increases CVD risk and explains possible interventions to correct acid-base balance and thus reduce the risk.

Read full article at: https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfz297/5719358

18 February 2020/by ERA-EDTA
https://www.era-edta.org/en/wp-content/uploads/2020/02/m_gfz149f1.png 248 520 ERA-EDTA ERA-EDTA2020-02-18 09:49:502020-02-18 09:49:50Serum bicarbonate as a cardiovascular risk factor

Clinical considerations and strategies for treating hypertension in CKD patients

News, News-Home

Hypertension is both a major cause and consequence of chronic kidney disease (CKD). It is associated with increased risk of cardiac events, stroke and kidney disease progression. The latest National Kidney Foundation Clinical Practice Guidelines recommend a blood pressure goal of <130mmHg systolic and <80mmHg diastolic for all CKD patients, regardless of the level of albuminuria. Several non-pharmacological interventions are recommended to achieve this, including weight loss, salt intake restriction and physical activity. As for pharmacological treatment, a combination of renin-angiotensin system (RAS) blocker (either ACE inhibitor or ARB, in case of ACE inhibitor intolerance) with a calcium channel blocker or a diuretic is recommended as initial therapy in patients with CKD stage 3 or higher. A combination of two RAS blockers is not recommended

Read the article https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfz279/5700448

31 January 2020/by ERA-EDTA
https://www.era-edta.org/en/wp-content/uploads/2019/10/patient_img_home.jpg 700 1000 ERA-EDTA ERA-EDTA2020-01-31 11:36:442020-01-31 11:36:44Clinical considerations and strategies for treating hypertension in CKD patients

World Diabetes Day: Chronic Kidney Disease due to diabetes is a serious public health threat!

News, News-Home

Diabetes is one of the key drivers of chronic kidney disease and the most frequent reason why patients are in need of renal replacement therapy. Conversely, outcomes for dialysis patients with diabetes are rather poor. For these reasons, the ERA-EDTA aims to raise awareness of the threat of kidney disease on World Diabetes Day on November 14. It is important to prevent diabetes wherever possible and if not, to take great care to ensure that kidney health is protected in diabetic patients. SGLT2 inhibitors have the potential to treat CKD in patients with diabetes.

“On World Diabetes Day (WDD) we support diabetes associations in their important goal of raising awareness for the risk factors of diabetes. But we also have to maintain kidney health in patients with diabetes for as long as possible” says Carmine Zoccali, President of the ERA-EDTA.

Read more here

14 November 2019/by ERA-EDTA
https://www.era-edta.org/en/wp-content/uploads/2019/11/WDD19-Facebook-Cover-Photo-820x312px-300dpi.png 304 800 ERA-EDTA ERA-EDTA2019-11-14 11:57:562019-11-14 11:57:56World Diabetes Day: Chronic Kidney Disease due to diabetes is a serious public health threat!

Over 850 million people worldwide have some form of kidney disease

News, News-Home

On a world scale the total number of individuals with chronic kidney disease (CKD), acute kidney injury (AKI), and those on renal replacement therapy (RRT) exceeds 850 million, a truly concerning figure that is twice the estimated number of people with diabetes worldwide and >20 times higher than the number of individuals affected by AIDS/HIV worldwide. Thus kidney diseases are one of the most common diseases worldwide.

Find out more on NDT here

9 October 2019/by ERA-EDTA
https://www.era-edta.org/en/wp-content/uploads/2019/10/12310.jpg 706 1038 ERA-EDTA ERA-EDTA2019-10-09 12:34:492019-10-16 12:37:44Over 850 million people worldwide have some form of kidney disease
  • The risks of gastrointestinal adverse events with initiation of sodium polystyrene sulphonate19 October 2020 - 10:55
  • Are all donated kidneys the same?16 October 2020 - 11:40
  • Which phosphate transporters should be targeted to reduce hyperphosphatemia?14 October 2020 - 10:02
  • Does ADH modulate renal calcium excretion in patients with CDI and hypercalciuria?12 October 2020 - 16:31

ERA-EDTA Operative Headquarters
Via XXIV Maggio 38
43123 Parma – Italy
Phone: +39 0521 989078
Fax: +39 0521 959242
E-mail: secretariat@era-edta.org

ERA-EDTA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom

You are here: Home / chronic kidney disease

  • ABOUT ERA-EDTA
  • CONGRESS & MEETINGS
  • JOURNAL & PRESS
  • EDUCATION
  • PUBLIC AFFAIRS
  • GUIDELINES

  • My ERA-EDTA
  • Contact us
  • MEMBERSHIP
.av-share-box ul li{ display: none!important; }

  • Share on Facebook
  • Share on Twitter
  • Share on Pinterest
  • Share on Linkedin
  • Share on Reddit
  • Share by Mail
  • Share on WhatsApp
© Copyright - Era-Edta
  • Terms and Conditions
  • Cookie Policy
  • Privacy Policy
  • Facebook
  • Instagram
  • Youtube
  • Linkedin
  • Twitter
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more